WebBackground: The use of prostate-specific antigen (PSA) thresholds (<0.2 ng/ml) below currently accepted biochemical recurrence (BCR) definitions for patients treated with radical prostatectomy may be useful in the identification of candidates for early salvage therapy with improved outcome; however, the practice risks overtreatment, as the risk of … WebBiochemical recurrence. With a mean follow-up of 21.9 months, 26 patients (60%) reached a serum PSA nadir less than 0.1 ng/ml (undetectable), 16 (37%) had a PSA less than 4 …
An Australian experience using Tc‐PSMA SPECT/CT in the primary ...
WebThe incidence of prostate cancer biochemical recurrence is around 15% to 30% within 5 years and about 40% within 10 years after radical prostatectomy. 5 Once biochemical recurrence occurs, many prostate cancer patients are inclined to progress to be resistant to androgen deprivation therapy, which is also called castration-resistant prostate ... WebBiochemical recurrence without metastatic disease after exhaustion of local treatment options . Biochemical recurrence is defined as a rise in PSA to 0.2 ng/mL and a … city wireless repair
Consensus on Treatment and Follow-Up for Biochemical Recurrence …
WebJan 7, 2024 · Our aims were to identify prognostic factors for late biochemical recurrence, including cancer family history, and evaluate cancer specific mortality. Materials and … WebFeb 2, 2024 · The cumulative incidence of a second biochemical recurrence at 12 years was 44.0% in the bicalutamide group, as compared with 67.9% in the placebo group (hazard ratio, 0.48; 95% CI, 0.40 to 0.58 ... WebProstate-specific antigen (PSA) defined biochemical recurrence (BCR) of prostate cancer is widely used for reporting the outcome of radical prostatectomy (RP). A standardized BCR definition is lacking, and overall progression-free probability and risk of subsequent metastatic disease progression may vary greatly depending on the PSA ... dougherty county divorce records